BioWorld

July 29, 2004

Cell Therapeutics Adds To Cash With $42.8M Offering

Laden with the expense of pivotal trials, Cell Therapeutics Inc. raised $42.8 million to give it the reserves to last through 2005. (BioWorld Today) Read More

With Antegren Launch Expected, Biogen Idec Tops 2Q Estimates

MannKind IPO Prices Within Range; Shares Close Higher

New BioDefense Guide Released With 37 Company Success Stories

Lexicon, Takeda In Agreement For High Blood Pressure Drugs

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 19, 2026.

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...